Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review discusses the increased prevalence of androgenic alopecia in men and women, highlighting the limited FDA-approved treatment options, and reports no clinical results; the authors note adherence challenges due to prolonged drug use.

In this study, researchers developed a new topical atraric acid formulation, AA-TF#15, which showed a significantly higher drug penetration and increased hair regrowth in mice compared to minoxidil and finasteride treatments, suggesting its potential effectiveness for treating scalp androgenic alopecia.

In this study, researchers observed that in advanced androgenetic alopecia, increased DNA damage in the frontal bald area may lead to cell apoptosis due to impaired repair capacity.

In this animal study, AGO (agomelatine) effectively alleviated testosterone-induced benign prostatic hyperplasia in rats by reducing oxidative stress and inflammation, indicating its potential as a therapeutic option for managing BPH through specific signaling pathways.

This review concluded that while topical prostaglandin analogues show some potential in treating androgenetic alopecia, evidence is still limited and no products have regulatory approval.

This review discusses female androgenic alopecia, highlighting its potential difference from male androgenic alopecia and notes increased incidence, but reports no new clinical findings.

This study found that the rs3185480 polymorphism in the APCDD1 gene was associated with an elevated risk of developing androgenic alopecia and reduced protein levels, potentially due to altered codon usage affecting translation efficiency.

This article traces the origin of the term "androgenetic" and discusses the progressive nature of androgenetic alopecia with age, reporting no new research findings.

In this study, researchers identified two independent genetic variants near the androgen receptor gene strongly associated with androgenetic alopecia in men.

This study found that PPARα agonists provided protective effects in mouse models of alopecia areata by promoting early reversal of the condition and inhibiting T effector cell function, indicating potential therapeutic value for this inflammatory condition.

This review discusses platelet-rich plasma treatment for androgenetic alopecia, addressing its effectiveness, challenges, and future directions, but reports no new clinical results.

This study developed a microneedle system using black phosphorus nanosheets and baicalin for treating androgenetic alopecia, finding it effectively enhanced drug penetration and follicular targeting while showing synergistic efficacy and safety in preclinical tests, including in vivo model efficacy against testosterone-induced hair loss.

This review discusses the potential benefits of platelet-rich plasma (PRP) for treating androgenic alopecia in athletes and examines how physical activity might influence androgen levels, but it reports no new results.

In this study, the researchers explored how the loss of structural integrity in hair follicles due to reduced α-SMA expression in the vertex area may contribute to androgenetic alopecia.

This study found that certain trichoscopic features like white peripilar sign, yellow dots, and scalp pigmentation are positively correlated with the severity of androgenetic alopecia in Chinese patients.

In this study, 4‐MAPC treatment reduced ventral prostate weight in rats primarily through decreased synthetic activity, with testosterone propionate increasing prostate weight and activity at pharmacologic doses.

This article explores the potential applications of polyglutamic acid in cosmetics, discussing its benefits for skincare and haircare, but reports no new experimental results.

This study observed that patients with androgenetic alopecia had significantly higher serum FABP4 levels compared to healthy controls, suggesting FABP4 may be involved in the condition's pathogenesis.

This article discusses the impact of androgenetic alopecia, highlighting its genetic and hormonal causes and its significant psychological and quality of life effects, but reports no new clinical findings.

This article discusses the term "androgenetic alopecia" proposed to replace "male pattern alopecia," noting its limited use in American dermatology literature.

This article reviews the possible therapeutic activities of Angelica gigas Nakai root extracts and their components, noting their potential effects on neuro-cognitive, metabolic, and other health conditions, and reports no new clinical results.

This study found that serum GPER-1 levels were significantly higher in patients with androgenetic alopecia compared to healthy controls, suggesting a potential role in the condition's pathogenesis, independent of gender.

In this study, Sper-12/siRNA nanoparticles effectively suppressed abnormal AR protein levels, promoted hair follicle proliferation, and alleviated hair loss symptoms in androgenetic alopecia model mice, providing a promising delivery platform for siRNA-based therapeutics.

This expert group provided recommendations for preparing and using platelet-rich plasma in treating androgenetic alopecia, suggesting a manual double-spin method and specific dosing, although further studies on injectable platelet-rich fibrin are needed.

This review discusses the current literature on platelet rich plasma injections for androgenetic alopecia, noting that while some studies report positive outcomes, they often suffer from methodological weaknesses and inconsistent results.

This review discusses the molecular mechanisms of androgenetic alopecia and evaluates current and potential treatments, highlighting the limitations of minoxidil and finasteride and exploring newer approaches like growth factors and cytokines, topical 5-alpha-reductase inhibitors, and platelet-rich plasma injections as more effective and safer alternatives.

In this study, candidate compound 39 demonstrated potent androgen receptor antagonism and faster hair-growth efficacy in a mouse model compared to pyrilutamide, while maintaining favorable safety and pharmacokinetic profiles, suggesting potential for topical use in androgenic alopecia.

In this study, researchers found that sesamin, a component of sesamum, modulated the AR-MAPK-Wnt signaling pathway in DHT-stimulated HaCaT keratinocytes, demonstrating potential multi-target activity against molecular events in androgenetic alopecia.

This study demonstrated that ablation of individual somatostatin-expressing interneurons increased activity in nearby neurons of the mouse motor cortex during motor learning.